These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 9520154)

  • 1. Differential resistance to anthracyclines in P-glycoprotein-expressing human hepatoma cells.
    Lehne G; De Angelis P; Clausen OP; Rugstad HE
    Int J Clin Pharmacol Ther; 1998 Feb; 36(2):89-92. PubMed ID: 9520154
    [No Abstract]   [Full Text] [Related]  

  • 2. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.
    Lehne G; De Angelis P; Clausen OP; Rugstad HE
    Br J Cancer; 1996 Dec; 74(11):1719-29. PubMed ID: 8956784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of P-glycoprotein in rat hepatoma rho(o) cells: implications for drug-DNA interactions.
    Pillay V; Martinus RD; Hill JS; Phillips DR
    J Cell Biochem; 1998 Jun; 69(4):463-9. PubMed ID: 9620172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporin A and PSC 833 prevent up-regulation of MDR1 expression by anthracyclines in a human multidrug-resistant cell line.
    Hu XF; Slater A; Wall DM; Parkin JD; Kantharidis P; Zalcberg JR
    Clin Cancer Res; 1996 Apr; 2(4):713-20. PubMed ID: 9816222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationship between anthracycline-induced differentiation and inhibition of glycoprotein synthesis in Friend erythroleukemia cells.
    Schaefer A; Dahle M; Radenz G; Steinheider G; Marquardt H
    Leukemia; 1991 Feb; 5(2):95-100. PubMed ID: 2020200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells.
    Siegsmund MJ; Stendler A; Kreukler C; Köhrmann KU; Alken P
    Eur Urol; 1997; 31(3):365-70. PubMed ID: 9129933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracyclines, proteasome activity and multi-drug-resistance.
    Fekete MR; McBride WH; Pajonk F
    BMC Cancer; 2005 Sep; 5():114. PubMed ID: 16159384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
    Tapiero H; Nguyen-Ba G; Lampidis TJ
    Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of structural modifications of anthracyclines on the ability to overcome drug resistance of cancer cells.
    Wasowska M; Wietrzyk J; Opolski A; Oszczapowicz J; Oszczapowicz I
    Anticancer Res; 2006; 26(3A):2009-12. PubMed ID: 16827137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Studies on collagenase inhibitors. III. Inhibitory effects of anthracyclines on bacterial collagenase].
    Tanaka T; Metori K; Mineo S; Matsumoto H; Satoh T
    Yakugaku Zasshi; 1991 Jan; 111(1):70-2. PubMed ID: 1647453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming PGP-related multidrug resistance. The cyclosporine derivative SDZ PSC 833 can abolish the resistance to methoxy-morpholynil-doxorubicin.
    Michieli M; Damiani D; Michelutti A; Melli C; Ermacora A; Geromin A; Fanin R; Russo D; Baccarani M
    Haematologica; 1996; 81(4):295-301. PubMed ID: 8870372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells.
    Tsang WP; Kwok TT
    Oncogene; 2007 Jul; 26(33):4877-81. PubMed ID: 17297456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparative study on in vitro chemosensitivity of urotherial cancers to three anthracyclines].
    Yamada S; Deguchi T; Nezasa S; Kawamoto S; Ehara H; Takahashi Y; Okano M; Fujimoto Y; Isogai K; Kawada Y
    Gan To Kagaku Ryoho; 1996 Sep; 23(10):1339-41. PubMed ID: 8831750
    [No Abstract]   [Full Text] [Related]  

  • 15. Pirarubicin might partly circumvent the P-glycoprotein-mediated drug resistance of human breast cancer tissues.
    Kubota T; Furukawa T; Tanino H; Oura S; Murata H; Yuasa S; Morita K; Ueno J; Kozakai R; Yano T
    Anticancer Res; 1998; 18(2A):967-72. PubMed ID: 9615748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
    Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
    Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.
    Skovsgaard T
    Eur J Haematol Suppl; 1987; 47():7-20. PubMed ID: 3552720
    [No Abstract]   [Full Text] [Related]  

  • 18. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
    Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
    J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual mechanism of daunorubicin-induced cell death in both sensitive and MDR-resistant HL-60 cells.
    Côme MG; Skladanowski A; Larsen AK; Laurent G
    Br J Cancer; 1999 Mar; 79(7-8):1090-7. PubMed ID: 10098741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New anthracycline antibiotics and derivatives].
    Tatsuta K
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2640-52. PubMed ID: 6594977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.